מזומנים למניה אחת polyrizon-biotech.com (PLRZ)

Flexible R&D and manufacturing outsourcing protects Polyrizon Ltd from vendor risks. The cash per share metric visualizes this capital balance, where the 6.37 mark indicates the current state of liquidity. Swiss management ensures strict regulatory compliance, while business success relies on the commercialization of innovative nasal sprays for combating respiratory viruses.
פילוחים אנליטיים של חברת Polyrizon Ltd

Polyrizon Ltd focuses on developing innovative bio-gels for mucosal protection and is currently in the laboratory testing stage for polymers. This cash per share metric reflects the volume of liquid assets attributable to a single security. The metric allows for an assessment of the company's actual cash reserves, excluding market volatility. This chart reflects the issuer's ability to fund R&D cycles. High liquidity levels guarantee the project's operational stability during the preclinical testing period.